Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro
Authors:
Preprint
Abstract
Single domain shark VNAR antibodies can offer a viable alternative to conventional Ig-based monoclonal antibodies in treating COVID-19 disease during the current pandemic. Here we report the identification of neutralizing single domain VNAR antibodies selected against the SARS-CoV-2 spike protein derived from the Wuhan variant using phage display. We identified 56 unique binding clones that exhibited high affinity and specificity to the spike protein. Of those, 10 showed an ability to block both the spike protein receptor binding domain from the Wuhan variant and the N501Y mutant from interacting with recombinant ACE2 receptor in vitro . In addition, 3 antibody clones retained in vitro blocking activity when the E484K spike protein mutant was used. The inhibitory property of the VNAR antibodies was further confirmed for all 10 antibody clones using ACE2 expressing cells with spike protein from the Wuhan variant. The viral neutralizing potential of the VNAR clones was also confirmed for the 10 antibodies tested using live Wuhan variant virus in in vitro cell infectivity assays. Single domain VNAR antibodies due to their low complexity, small size, unique epitope recognition and formatting flexibility should be a useful adjunct to existing antibody approaches to treat COVID-19.Keywords
All Related Versions
- Published version: The FASEB Journal, 35 (11), e21970.
This publication has 47 references indexed in Scilit:
- SARS-CoV-2 vaccines in developmentNature, 2020
- Immunological considerations for COVID-19 vaccine strategiesNature Reviews Immunology, 2020
- SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune ReceptorsbioRxiv, 2020
- CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2bioRxiv, 2020
- A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung CellsMolecular Cell, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2Science, 2020
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020